BACKGROUND:Ancylostomatids ('hookworms') are among the most important zoonotic nematode parasites infecting dogs worldwide. Ancylostoma caninum and Uncinaria stenocephala are two of the most common hookworm species that infect dogs. Both immature and adult stages of hookworms are voracious blood feeders and can cause death in young dogs before infection can be detected by routine fecal examination. Hence, treatment of both immature and adult stages of hookworms will decrease the risk of important clinical disease in the dog as well as the environmental contamination caused by egg-laying adults, which should reduce the risk of infection for both dogs and humans. The studies presented here were conducted to evaluate the efficacy of a novel, oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™), against induced larval (L4), immature adult (L5) and adult A. caninum, and adult U. stenocephala infections in dogs. METHODS:Eight negative-controlled, masked, randomized laboratory studies were conducted. Two separate studies were conducted against each of the target parasites and stages. Sixteen or 18 purpose bred dogs, 8 or 9 in each of the two treatment groups, were included in each study. Dogs experimentally infected with the target parasite were dosed once on Day 0 with either placebo tablets or Simparica Trio™ tablets to provide minimum dosages of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5.0 mg/kg pyrantel (as pamoate salt). Timing of dosing relative to parasite inoculation allowed for efficacy to be evaluated primarily against the target parasite stage. Worm counts were conducted 7 or 8 days after treatments during necropsy. Efficacy was based on the number of worms recovered at necropsy compared to placebo control. RESULTS:Based on geometric mean worm counts, efficacy of Simparica Trio™ was ≥ 98.4% against L4 larval stage of A. caninum, ≥ 99.8% against immature adult (L5) A. caninum, and 100% against adult A. caninum and adult U. stenocephala. CONCLUSIONS:These studies confirm the efficacy of a single oral dose of a novel, chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against L4 larval and immature adult (L5) A. caninum, and adult A. caninum and U. stenocephala infections in dogs.

译文

背景技术:钩虫(钩虫)是全世界感染犬的最重要的人畜共患线虫寄生虫。犬十二指肠瘤和钩头畸形犬是感染狗的两种最常见的钩虫。钩虫的未成熟阶段和成年阶段都是贪食者,它们可以使幼犬死亡,然后才能通过常规粪便检查发现感染。因此,对钩虫的未成熟阶段和成年阶段的治疗都将降低犬中发生重要临床疾病的风险以及成虫产卵所造成的环境污染,这将降低犬和人的感染风险。此处进行的研究旨在评估含有sarolaner,moxidectin和pyrantel(Simparica Trio™)的新型口服咀嚼片对诱导幼虫(L4),成年幼虫(L5)和成年犬链霉菌以及成年U的功效。狗的头颅感染。
方法:进行了八项阴性对照,隐蔽,随机实验室研究。针对每个目标寄生虫和阶段进行了两个单独的研究。每项研究均包括16只或18只目的犬,两个治疗组分别为8只或9只。实验上感染目标寄生虫的狗在第0天用安慰剂片剂或Simparica Trio™片剂给药一次,以提供最低剂量1.2毫克/千克sarolaner,24微克/千克莫昔克丁和5.0毫克/千克吡喃酮(作为pamoate盐)。相对于寄生虫接种的给药时间允许主要针对目标寄生虫阶段评估功效。尸检后7或8天进行蠕虫计数。功效是基于尸检时与安慰剂对照相比发现的蠕虫数量。
结果:基于蠕虫的几何平均数,Simparica Trio™对抗犬链球菌L4幼虫期的效率≥98.4%,针对未成年犬(L5)犬链球菌的≥99.8%,对成年犬链球菌和成虫的功效为100%头颅单胞菌。
结论:这些研究证实了单次口服的含有sarolaner,moxidectin和pyrantel(Simparica Trio™)的新型可咀嚼片剂对L4幼虫和未成年成年犬L. A. caninum以及成年成年犬A. caninum和U的功效。狗的头颅感染。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录